3.28 USD
-0.11
3.24%
At close May 14, 4:00 PM EDT
After hours
3.28
+0.00
0.00%
1 day
-3.24%
5 days
-10.38%
1 month
-28.23%
3 months
-43.35%
6 months
-30.36%
Year to date
-35.94%
1 year
-57.89%
5 years
-54.38%
10 years
-63.23%
 

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 395

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

35% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 34

18% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 62

4% more funds holding

Funds holding: 201 [Q3] → 210 (+9) [Q4]

3.09% more ownership

Funds ownership: 60.59% [Q3] → 63.68% (+3.09%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

22% less capital invested

Capital invested by funds: $982M [Q3] → $765M (-$218M) [Q4]

23% less call options, than puts

Call options by funds: $14.5M | Put options by funds: $18.9M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5.50
68%
upside
Avg. target
$10.90
232%
upside
High target
$15
357%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
Citigroup
Yigal Nochomovitz
11% 1-year accuracy
4 / 36 met price target
205%upside
$10
Buy
Maintained
2 May 2025
Scotiabank
Louise Chen
23% 1-year accuracy
26 / 113 met price target
357%upside
$15
Sector Outperform
Initiated
7 Mar 2025
Ladenburg Thalmann
Aydin Huseynov
14% 1-year accuracy
1 / 7 met price target
235%upside
$11
Buy
Assumed
7 Mar 2025
Raymond James
Ryan Deschner
91% 1-year accuracy
10 / 11 met price target
296%upside
$13
Strong Buy
Reiterated
21 Feb 2025
HC Wainwright & Co.
Ed Arce
41% 1-year accuracy
57 / 140 met price target
68%upside
$5.50
Neutral
Reiterated
21 Feb 2025

Financial journalist opinion

Based on 24 articles about ARDX published over the past 30 days

Neutral
Accesswire
17 hours ago
ATTENTION ARDX Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
ATTENTION ARDX Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
Neutral
Accesswire
18 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Neutral
Accesswire
1 day ago
An Investigation Has Commenced on Behalf of Ardelyx, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARDX Losses
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
An Investigation Has Commenced on Behalf of Ardelyx, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARDX Losses
Neutral
GlobeNewsWire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Neutral
Accesswire
2 days ago
Investors Who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - ARDX
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Investors Who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - ARDX
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Neutral
Accesswire
2 days ago
Investors who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - ARDX
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Investors who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - ARDX
Neutral
Accesswire
4 days ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Ardelyx, Inc. (ARDX)
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Ardelyx, Inc. (ARDX)
Neutral
Accesswire
4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Neutral
Accesswire
5 days ago
Ardelyx, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Ardelyx, Inc. (ARDX)
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Ardelyx, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Ardelyx, Inc. (ARDX)
Charts implemented using Lightweight Charts™